Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BOP antibacterial peptide mouthwash is a therapeutic oral rinse formulated with antimicrobial peptides (AMPs) specifically designed to address halitosis (bad breath). The product is being evaluated in clinical settings, including studies led by the Hospital of Stomatology at Shandong University, to assess its ability to reduce volatile sulfur compounds (VSCs) and improve subjective breath quality. The active antibacterial peptides function by targeting and disrupting the cell membranes of odor-producing oral bacteria, offering a potentially more targeted approach than traditional broad-spectrum antiseptic mouthwashes. It is typically administered as a topical oral solution.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BOP antibacterial peptide mouthwash.